Obviously, it's interesting, in that there are two different ways of going about it. It seems that almost the more specific the drug.... The cancer people didn't seem very happy with having their drug declined, in terms of kidney cancer, and, Louise, we're hearing from you that you have also had a similar experience.
It sounds like people feel that if practitioners and citizens and patients were more involved in the decisions, maybe you would get a better outcome. I'm worried that I'm hearing that the only answer is to just abandon it, when at the same time I understand from the national pharmaceuticals strategy that we would like one day to end up with a national formulary.
If that's the case, and the EU can do that, and we've got five formularies for the federal government alone, how do we move to this goal of a national formulary? What would that look like? If you were writing the recommendations for this committee, how do we use the problems and some successes with the CDR to get us to what we really want, which would be that regardless of where you live in this country, you get the drugs you need?